The inaugural Oxford Oesophagogastric Cancer Centre of Excellence Symposium took place on Tuesday, 25th February, at Lincoln College, Oxford. The event brought together collaborators from across Oxford and further afield who share a commitment to advancing research into and treatment for oesophagogastric cancer.
Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with OCION Pump Prime awardee - Dr. Tamsin Cargill - to discuss her research.
A new study led by researchers from Oxford Population Health has shown that a range of environmental factors have a greater impact on health and premature death than our genes. The researchers used data from nearly half a million UK Biobank participants to assess the influence of 164 environmental factors and genetic risk scores for 22 major diseases (including some cancers) on ageing, age-related diseases, and premature death.
New research - published today in Nature Communications - shows why there are differences in prognosis between different pancreatic tumours and identifies potential avenues for improved treatment approaches.
On World Cancer Day, Dr Sharon Tonner reflects on the theme 'United by Unique', sharing how the team in the Nuffield Department of Primary Care and Health Sciences is navigating and addressing the need for patient-centered care and inclusive, equitable research.
Researchers in NDM have authored a collaborative study which explored a new method for detecting bowel cancer, which was found to be more than 90% accurate at predicting which higher-risk people will develop this type of cancer in the future.
Two early-career postdoctoral researchers at the Department of Oncology - Ahmet Hazini and Esther Ng - have secured funding to deliver pioneering research projects that aim to advance the field of cancer immunotherapy.
Global biopharma company GSK invests up to \u00a350 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.
Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with OCION Pump-Prime Awardee, Associate Professor Audrey Gerard, to discuss her research.
Oxford University researchers have unveiled a new blood test \u2013 powered by machine learning \u2013 which shows real promise in detecting multiple types of cancer in their earliest stages, when the disease is hardest to detect.
Spin-out company Alethiomics, focused on the development of innovative treatments for blood cancers, is Oxford through-and-through. Founded by Clinician Scientists who run neighbouring laboratories at the University\u2019s MRC Weatherall Institute of Molecular Medicine, seed financed by Oxford Science Enterprises and located at the BioEscalator, the company\u2019s early years have been immersed in the Oxford innovation ecosystem.
RDM researchers have outlined the potential benefits and limitations of new spatial transcriptomic technologies for mapping the bone marrow in patients with blood cancer.
Recent research from the S:CORT team spanning three publications has identified key biomarkers and treatment strategies that predict and enhance effectiveness of radiotherapy in rectal cancer treatment.
Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Dr. Ad\u00e1n Pinto-Fern\u00e1ndez to discuss his research.
Researchers at the University of Oxford, the Francis Crick Institute and University College London have been granted funding from Cancer Research UK (CRUK) and the CRIS Cancer Foundation to develop \u2018LungVax\u2019, the world\u2019s first vaccine to prevent lung cancer in people with a high risk of the disease. Hear from LungVax team members Professor Sarah Blagden, Professor Mariam Jamal-Hanjani and Patient and Public Involvement Representative Janette Rawlinson in this video interview from CRUK.
Researchers at the University of Oxford, the Francis Crick Institute and University College London have been granted funding from Cancer Research UK and the CRIS Cancer Foundation to develop \u2018LungVax\u2019, the world\u2019s first vaccine to prevent lung cancer in people with a high risk of the disease. CRUK have produced a short explainer animation, giving an insight into how LungVax is intended to work.
The Oxford Cancer Symposium supported by the CRUK Oxford Centre is the crowning event in the Oxford Cancer calendar. With approximately 300 people attending in person each year, it provides an opportunity for our members to network and build new collaborations.
Oxford Cancer, the Oxford Vaccine Group and the Pandemic Sciences Institute have announced a new collaboration with Belgian Biotech Innovator, Univercells.
Three projects \u2013 including the Oxford-led MyMelanoma study - have been selected to join an NHS initiative, which aims to sign up tens of thousands of volunteers over the next two years to help improve the diagnosis and treatment of cancer patients.
![\"\"](\"https://www.cancer.ox.ac.uk/news/oxford-cancer-hosts-inaugural-oesophagogastric-cancer-centre-of-excellence-symposium/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n